hematology analyzers & regents market global forecast
march 15, 2016
widely used in clinical testing laboratories, hospitals, and research institutions, hematology analyzers are indispensable for the diagnosis of various diseases, such as infections, anemia, viruses, diabetes, genetic problems and cancer.
point-of-care analyzers improve patient care and clinical outcomes
march 1, 2016
with emerging technological innovations, point-of-care (poc) technologies are transforming the healthcare landscape, providing quick results to improve care and maximize office efficiencies. leaders in this market include: abbott, siemens, diazyme and stanbio.
abbott acquires alere to gain leadership in point-of-care segment
february 16, 2016
abbott laboratories, a worldwide healthcare company leader, has reached an agreement to acquire alere inc. a diagnostics-testing company for $5.8 billion. alere’s complementary point-of-care technologies will help abbott provide better care for patients by meeting the growing demand for fast, accurate, and actionable medical information.
continued growth for beckman access ii immunoassay systems
february 2, 2016
beckman coulter diagnostics received 510(k) clearance from the u.s. food and drug administration (fda) for the access 25(oh) vitamin d total assay in 2015. this new, innovative assay is available for use on beckman coulter’s access ii and unicel dxi series of immunoassay systems.
emerging opportunities in the global drugs of abuse testing market
january 19, 2016
according to a recent trends and analysis report from research & markets, the global drugs of abuse (doa) testing market is expected to grow steadily in 2016 and beyond.
happy new year from block scientific!
december 29, 2015
as 2015 draws to a close, block scientific is all set to ring in the new year with the resolve to continue offering the best customer service. here’s a look at some of the top news we highlighted in 2015.
global drugs of abuse testing market to hit $4 billion by 2020
december 15, 2015
testing for drugs of abuse is performed in a variety of settings for addiction treatment, medical determinations, and to provide a quick index of drug-related problems. according to a recent report from p&s market research, the global drug of abuse (doa) testing market is expected to reach $3.9 billion in 2020.
greiner bio-one and scienion collaborate to develop rapid diagnostic tests
december 1, 2015
greiner bio-one and scienion ag have entered into an agreement for the development of advanced tests and integrated solutions for rapid and multiplexed diagnostics. by bringing together scienion’s core competencies in ultra-low volume liquid dispensing, assay miniaturization, and microarray manufacturing with greiner bio-one’s innovative genspeed® testing system, the collaboration sets new goals to optimize treatment outcomes for patients.